Posted by Michael Wonder on 10 May 2022
ICER publishes final evidence report and policy recommendations on outpatient treatments for COVID-19
10 May 2022 - Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit for molnupiravir over symptomatic care alone; Paxlovid and fluvoxamine receive more favourable votes.
The ICER today released a Final Evidence Report assessing the comparative clinical effectiveness and value of the following outpatient treatments for COVID-19:
- Molnupiravir (Merck)
- PF-07321332/ritonavir (Paxlovid, Pfizer)
- fluvoxamine (Investigator initiated)
